Table 1.
Results of immunohistochemistry
| Score |
||||
|---|---|---|---|---|
| Diagnosis (number of cases) | Case | FAP | DPP-IV | |
| Low-grade myofibroblastic sarcoma (N = 2) | 1 | 3 | 3 | |
| 2 | 3 | 2 | ||
| Osteosarcoma | 3 | F | 2 | 2 |
| Fibroblastic type (N = 2) | O | 1 | 0 | |
| C | 0 | 0 | ||
| 4 | F | 2 | 0 | |
| O | 1 | 0 | ||
| C | 0 | 0 | ||
| Osteoblastic type (N = 8) | 5 | F | 2 | 0 |
| O | 0 | 0 | ||
| C | - | - | ||
| 6 | F | 3 | 3 | |
| O | 1 | 1 | ||
| C | - | - | ||
| 7 | F | 3 | 3 | |
| O | 1 | 0 | ||
| C | - | - | ||
| 8 | F | 2 | 2 | |
| O | 0 | 1 | ||
| C | 0 | 0 | ||
| 9 | F | 1 | 2 | |
| O | 0 | 1 | ||
| C | 0 | 0 | ||
| 10 | F | 2 | 3 | |
| O | 0 | 0 | ||
| C | 0 | 0 | ||
| 11 | F | 1 | 3 | |
| O | 0 | 0 | ||
| C | - | - | ||
| 12 | F | 2 | 3 | |
| O | 0 | 0 | ||
| C | 0 | 0 | ||
| Chondroblastic type (N = 1) | 13 | F | 1 | 2 |
| O | 0 | 0 | ||
| C | 0 | 0 | ||
| Malignant fibrous histiocytoma (N = 4) | 14 | 0 | 3 | |
| 15 | 0 | 3 | ||
| 16 | 3 | 3 | ||
| 17 | 2 | 3 | ||
| Rhabdomyosarcoma (N = 4) | 18 | 0 | 0 | |
| 19 | 0 | 0 | ||
| Ewing’s sarcoma (N = 4) | 20 | 0 | 0 | |
| 21 | 0 | 0 | ||
| 22 | 0 | 0 | ||
| 23 | 0 | 0 | ||
| Adamantinoma (N = 1) | 24 | 0 | 0 | |
| Non-ossifying fibroma (N = 1) | 26 | 3 | 3 | |
| Giant cell tumor (N = 4) | 27 | G | 1 | 3 |
| M | 2 | 1 | ||
| F | 2 | 1 | ||
| 28 | G | 1 | 3 | |
| M | 1 | 2 | ||
| F | 2 | 1 | ||
| 29 | G | 3 | 3 | |
| M | 0 | 3 | ||
| F | 1 | 2 | ||
| 30 | G | 1 | 3 | |
| M | 1 | 3 | ||
| F | 2 | 2 | ||
| Desmoid (N = 1) | 31 | 2 | 3 | |
| Chondroblastoma (N = 1) | 32 | 2 | 2 | |
| Schwannoma (N = 3) | 33 | 0 | 1 | |
| 34 | 0 | 0 | ||
| 35 | 1 | 0 | ||
| Lipoma (N = 1) | 36 | 0 | 0 | |
| Elastofibroma (N = 1) | 37 | 0 | 0 | |
| Osteoid osteoma (N = 1) | 38 | 3 | 3 | |
| Granulation tissues | 3 | 3 | ||
Evaluation method for HER2 immunoreactivity was adopted for semiquantification. Pleomorphic malignant fibrous histiocytoma is also referred to as ‘undifferentiated pleomorphic high-grade sarcoma’.
F, fibroblastic area; O, osteoblastic area; C, chondroblastic area; G, giant cells; M, mononuclear cells; FAP, fibroblast activation protein; DPP-IV, dipeptidylpeptidase-IV.